VMP35 MNC, a novel iron-free supplement, enhances cytoprotection against anemia in human subjects: a novel hypothesis.Corbier JR, Downs BW, Kushner S, Aloisio T, Bagchi D, Bagchi M.Food and Nutrition Research. 2019 May 9;63.
Abstract:
Background: The American Society of Hematology reported that according to the National Heart, Lung, and Blood Institute (NHLBI) anemia is the most common blood disorder, which affects more than 3 million Americans, while the Global Burden of Disease 2016 (GBD 2016) reported that iron deficiency anemia (IDA) is the leading cause of anemia, which affects 1.93 billion people worldwide. Anemia is intricately linked to chronic inflammation, chronic kidney disease, gastrointestinal and gynecological malignancies, and autoimmune disorders. Hemorrhagic anemia results in substantial loss of blood, which causes significant alterations in all blood parameters, including reduced iron. The other type of anemia is chronic anemia syndrome (CAS), which is a constellation of disorders and chronic inflammatory events caused by an increasing anaerobic/acidic environment (promoting the growth of anaerobic organisms), inducing a defensive expenditure of alkalinizing buffers in hemoglobin (i.e. histidine), to prevent a dangerous lowering of blood pH. In this process, iron is cleaved from heme groups and transferred out of blood circulation into other organs, like the liver, appearing to be IDA, where excessive accumulation can lead to hemochromatosis, also known as 'iron overload anemia'.
Design: A pilot clinical study was conducted in 38 subjects (men = 10; women = 28; age = 22-82 years) to evaluate the rate of absorption and effects on blood of VMP35 multi-nutrient complex (MNC), a non-iron containing liquid nutraceutical supplement. Subjects consumed either placebo or VMP35 (30 mL) over a period of 0, 5, or 30 min.
Methods: Changes in peripheral blood smears from 38 subjects were observed using live blood cell imaging (LBCI) with phase contrast microscopy. Adverse events were rigorously monitored.
Results: VMP35 caused positive changes in the blood, including morphological, hematological (including restoration of hemoglobin), and rheological changes following 5 min of administration, which were sustained for at least 30 min.
Conclusions: Overall, the non-iron containing VMP35 can induce improvements in blood properties and potential benefits for subjects even with compromised digestive systems. No adverse events were reported. Further research studies are in progress to explore the mechanistic insight.
Key Points:
➢ RBC and blood rheology improvements were observed demonstrating that VMP35 encapsulated in multilamellar SK713 SLP Prodosome architecture was delivered and absorbed by sublingual trans-mucosa within 5 min.
➢ PBS LBCI offers a unique ability to observe the rapid onset of hematological changes in response to interventions.
➢ Changes were observed within 5 min of VMP35 administration, which were sustained for at least 30 min. Group 2 at 5 min and Group 3, at 5 and 30 min supports the validity of the observations. No effect was observed in the control group. Prompt, sustained and progressive findings were observed in the Treatment groups.
➢ Overall, the SK713 SLP delivery technology of the VMP35 MNC was shown to exert rapid positive restorative response on morphological, hematological, and rheological properties of the blood, reversing chronic anemia conditions, which challenges the premise of Iron Deficiency Anemia.
Prodovite Clinical StudyFull ManuscriptLEDERACH, Pa., June 4, 2019 (Newswire.com)
